pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,878 catalysts · 4,779 phase readout · 2,339 8k filing · 285 earnings · 271 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,779
  • 8k filing2,339
  • earnings285
  • pdufa271
  • phase 2 completion166
  • phase 1 completion71
  • phase 2 initiation54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 27, 2026

    50
    ›Apr 28, 20268k filing87d ago$BCDA — BioCardia, Inc. (BCDA) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$ALLR — Allarity Therapeutics, Inc. (ALLR) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d agoSilexion Therapeutics Corp (SLXN, SLXNW) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$BMEA — Biomea Fusion, Inc. (BMEA) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$ARAY — ACCURAY INC (ARAY) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$CLYM — Climb Bio, Inc. (CLYM) — 8-K filing

    Items: 1.01, 3.02, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$GILD — GILEAD SCIENCES, INC. (GILD) — 8-K filing

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$ACET — Adicet Bio, Inc. (ACET) — 8-K filing

    Items: 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$ACLX — Arcellx, Inc. (ACLX) — 8-K filing

    Items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$DSGN — Design Therapeutics, Inc. (DSGN) — 8-K filing

    Items: 2.02, 7.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$NRC — NRC HEALTH (NRC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$OPK — OPKO HEALTH, INC. (OPK) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$VTGN — Vistagen Therapeutics, Inc. (VTGN) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$LABT — Lakewood-Amedex Biotherapeutics Inc. (LABT) — 8-K filing

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d agoSeaStar Medical Holding Corp (ICU, ICUCW) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$FLNA — FILANA THERAPEUTICS, INC. (FLNA) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$PTCT — PTC THERAPEUTICS, INC. (PTCT) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$HRGN — Harvard Apparatus Regenerative Technology, Inc. (HRGN) — 8-K filing

    Items: 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$MDGL — MADRIGAL PHARMACEUTICALS, INC. (MDGL) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$FENC — FENNEC PHARMACEUTICALS INC. (FENC) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$QNCX — Quince Therapeutics, Inc. (QNCX) — 8-K filing

    Items: 8.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$PREM — Premier Air Charter Holdings Inc. (PREM) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d agoScilex Holding Co (SCLX, SCLXW) — 8-K filing

    Items: 1.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$JANX — Janux Therapeutics, Inc. (JANX) — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$CTOR — CITIUS ONCOLOGY, INC. (CTOR) — 8-K filing

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$QUCY — Quantum Cyber N.V. (QUCY) — 8-K filing

    Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filing

    Items: 3.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 28, 20268k filing87d ago$LNAI — Lunai Bioworks Inc. (LNAI) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 29, 2026pdufa86d agoSanofi — teplizumab (PDUFA)teplizumab

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →teplizumab →source: globaldata
    ›Apr 29, 2026phase 0 trial completion86d agoDana-Farber Cancer Institute Inc — atezolizumab (Phase 0 Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 29, 2026phase 1 completion86d agoBoehringer Ingelheim International GmbH — BI-765179 (Phase I Trial Completion)BI-765179

    Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re

    full page →BI-765179 →source: globaldata
    ›Apr 29, 2026phase 1 completion86d agoUniversity of Washington — autologous mitochondria (Phase I Trial Completion)autologous mitochondria

    Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia

    full page →autologous mitochondria →source: globaldata
    ›Apr 29, 2026phase 1 completion86d agoAltasciences Co Inc — NN-7442 (Phase I Trial Completion)NN-7442

    Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)

    full page →NN-7442 →source: globaldata
    ›Apr 29, 2026phase 1 initiation86d agoTerSera Therapeutics LLC — goserelin LA (Phase I Trial Initiation)goserelin LA

    Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →goserelin LA →source: globaldata
    ›Apr 29, 2026phase 1 initiation86d agoOcugen Inc — adenovirus vector (spike protein) vaccine (Phase I Trial Initiation)adenovirus vector (spike protein) vaccine

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)

    full page →adenovirus vector (spike protein) vaccine →source: globaldata
    ›Apr 29, 2026phase 1 initiation86d agoAgios Pharmaceuticals Inc — AG-181 (Phase I Trial Initiation)AG-181

    Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)

    full page →AG-181 →source: globaldata
    ›Apr 29, 2026phase 1 initiation86d agoBayer AG — asundexian (Phase I Trial Initiation)asundexian

    Therapy area: Cardiovascular. Indication: Ischemic Stroke

    full page →asundexian →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoTexas Christian University — Alii Supplement (Phase II Trial Completion)Alii Supplement

    Therapy area: Nutritional Disorders. Indication: Unspecified Nutritional Disorders

    full page →Alii Supplement →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoNational Heart Lung and Blood Institute — danazol (Phase II Trial Completion)danazol

    Therapy area: Gastrointestinal, Genetic Disorders, Hematological Disorders, Respiratory. Indication: Cytopenia, Liver Fibrosis, Mutational Disorders, Pulmonary Fibrosis

    full page →danazol →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoBangalore Medical College and Research Institute — dinoprostone (Phase II Trial Completion)dinoprostone ER

    Therapy area: Dermatology. Indication: Vitiligo

    full page →dinoprostone ER →source: globaldata
    ›Apr 29, 2026phase 2 completion86d agoNational Institute of Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Women's Health. Indication: Menorrhagia

    full page →unani medicine →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoNefro Avillion Clinical Development LLC — siplizumab (Phase II Trial Initiation)siplizumab

    Therapy area: Immunology. Indication: Kidney Transplant Rejection

    full page →siplizumab →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoSawai Man Singh Medical College — phenylephrine (Phase II Trial Initiation)phenylephrine

    Therapy area: Cardiovascular. Indication: Hypotension

    full page →phenylephrine →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoKyowa Kirin Co Ltd — KK-4277 (Phase II Trial Initiation)KK-4277

    Therapy area: Immunology. Indication: Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus

    full page →KK-4277 →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation86d agoGovernment Medical College and Hospital Chandigarh — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ← prev
    page 6 of 158
    next →
    $AGIO36.28+0.64%
    $SNY43.36-0.98%
    $OCGN1.2700-1.55%